Want to see XRAY full AI Analyst Report?
XRAY Stock Chart & Stats
$12.93
$0.21(1.65%)
At close: 4:00 PM EDT
$12.93
$0.21(1.65%)
Day’s Range― - ―
52-Week Range$9.41 - $14.86
Previous CloseN/A
Volume3.96M
Average Volume (3M)5.74M
Market Cap
$2.68B
Enterprise Value$4.46K
Total Cash (Recent Filing)$190.00M
Total Debt (Recent Filing)$2.33B
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 06, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend Yield4.79%
Share Statistics
EPS (TTM)-3.15
Shares Outstanding200,326,680
10 Day Avg. Volume5,552,147
30 Day Avg. Volume5,740,378
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.83Price Target Upside6.99% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)1.42
Revenue Forecast (FY)$3.58B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Installed BaseDentsply Sirona’s core consumables and installed equipment create durable, repeat revenue streams. Consumables tied to routine procedures and service contracts produce predictable demand and margin support over time, cushioning revenue during capital-equipment cycles.
Improving Cash Flow And Active DeleveragingPositive operating cash flow improvement, ongoing free cash flow generation and meaningful debt retirements strengthen financial flexibility. Sustained cash generation and continued deleveraging reduce refinancing risk and provide resources to fund restructuring and targeted growth investments.
Product Innovation And Distribution ExpansionRecent launches (AI diagnostics, dental MRI, new endodontic systems) plus added distributor agreements bolster competitive positioning in digital dentistry. New product adoption and expanded channels can lift long-term equipment attach rates and follow-on consumable and service revenue.
Bears Say
Elevated LeverageMaterial rise in leverage reduces financial flexibility and increases vulnerability to demand shocks. A much thinner equity base magnifies earnings volatility, raises interest and covenant risk, and limits capacity for M&A or capital-intensive investments until balance sheet repair progresses.
Persistent Unprofitability And Margin PressureOngoing negative margins signal structural profit conversion issues: gross margins are reasonable but operating costs, mix shifts and tariffs are eroding profitability. Sustained unprofitability pressures retained cash, weakens ROE, and delays normalization of capital allocation decisions.
Distributor Destocking & Inventory Sell-through HeadwindDealer destocking and the pending ~$30M drop-ship inventory sell-through create structural near-term revenue and margin drag. Lower dealer inventories can suppress orders for equipment and consumables, extend recovery timing, and raise execution risk for return-to-growth targets.
DENTSPLY SIRONA News
XRAY FAQ
What was DENTSPLY SIRONA’s price range in the past 12 months?
DENTSPLY SIRONA lowest stock price was $9.40 and its highest was $14.86 in the past 12 months.
What is DENTSPLY SIRONA’s market cap?
DENTSPLY SIRONA’s market cap is $2.68B.
When is DENTSPLY SIRONA’s upcoming earnings report date?
DENTSPLY SIRONA’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were DENTSPLY SIRONA’s earnings last quarter?
DENTSPLY SIRONA released its earnings results on May 05, 2026. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.278 by -$0.008.
Is DENTSPLY SIRONA overvalued?
According to Wall Street analysts DENTSPLY SIRONA’s price is currently Undervalued.
Does DENTSPLY SIRONA pay dividends?
DENTSPLY SIRONA pays a Quarterly dividend of $0.16 which represents an annual dividend yield of 4.79%. See more information on DENTSPLY SIRONA dividends here
What is DENTSPLY SIRONA’s EPS estimate?
DENTSPLY SIRONA’s EPS estimate is 0.35.
How many shares outstanding does DENTSPLY SIRONA have?
DENTSPLY SIRONA has 200,326,680 shares outstanding.
What happened to DENTSPLY SIRONA’s price movement after its last earnings report?
DENTSPLY SIRONA reported an EPS of $0.27 in its last earnings report, missing expectations of $0.278. Following the earnings report the stock price went down -2.023%.
Which hedge fund is a major shareholder of DENTSPLY SIRONA?
Currently, no hedge funds are holding shares in XRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DENTSPLY SIRONA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.83 (6.99% Upside)
$13.83 (6.99% Upside)
Blogger Sentiment
Bullish
XRAY Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $515.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 51.2%
Last 30 Days ▲ 39.0%
Last 30 Days ▲ 39.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.26%
12-Months-Change
Fundamentals
Return on Equity
4.79%
Trailing 12-Months
Asset Growth
-13.57%
Trailing 12-Months
Company Description
DENTSPLY SIRONA
Dentsply Sirona Inc. is a global dental products and technologies company serving dental professionals, laboratories, and clinics. It operates across consumables and equipment/technology used in preventive, restorative, and specialty dentistry, offering products such as dental implants and implant solutions, orthodontic and endodontic products, restorative materials, and digital dentistry systems including CAD/CAM, imaging, and treatment-center equipment, along with related software and services.
XRAY Company Deck
XRAY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced mix of encouraging operational and financial actions alongside notable near-term challenges. Positives include improved operating cash flow, active deleveraging (≈$79–$80M debt retired), early cost savings (≈$20M OpEx reduction in Q1) and meaningful innovation launches (AI diagnostic aid with ~46% sensitivity improvement, dental MRI clearance, new endodontic tools). Management also maintained full-year guidance and highlighted distributor expansion and early commercial traction. Offsetting these are material constant-currency revenue declines (Q1 cc sales down 6.7%, down 4.5% excluding one-time items), significant margin compression (adjusted EBITDA down 430 bps; gross profit down 560 bps), softness in several key segments (OIS, EDS, IPS, CTS), tariff-related margin pressure, distributor destocking, and an expected ~$30M inventory sell-through headwind later in the year. Given the roughly balanced set of meaningful positives (cash, cost saves, innovation, distribution) and negatives (sales declines, margin pressure, macro/timing risks), the overall tone is cautiously constructive but realistic about near-term headwinds.View all XRAY earnings summariesXRAY Net sales Breakdown
15.71% Equipment & Instruments
12.45% CAD/CAM
39.92% Essential Dental Solutions
6.17% Orthodontics
16.93% Implants & Prosthetics
8.83% Wellspect Healthcare
XRAY Stock 12 Month Forecast
Average Price Target
$13.83
▲(6.99% Upside)
Technical Analysis
Ownership Overview
0.71% Insiders
32.56% Mutual Funds
9.20% Other Institutional Investors
33.99% Public Companies and
Individual Investors